Top 10 Best Bioconjugation Services of 2026

Lonza supports antibody and protein conjugation programs with defined coupling chemistries and purification workflows designed to control impurities and aggregates. Service deliverables commonly include analytical readouts such as size and species characterization plus LC–MS style assays used to quantify conjugation outcomes and free payload signals. Teams use this approach when conjugate performance depends on consistent drug-to-antibody ratio distributions and clear baselines for stability and comparability across batches.

A tradeoff appears in the integration overhead for site-specific operational alignment. Programs that need rapid, highly iterative conjugation design changes can experience slower turnaround versus smaller specialists. Lonza fits best when a bioconjugation program has defined chemistry goals and needs careful governance around batch comparability, purification decisions, and method consistency for in vitro and in vivo studies.

Sino Biological fits research teams that need repeatable conjugation execution across different target formats, including antibody-based and protein labeling programs that depend on controlled linker chemistry. Conjugation deliverables commonly include purification support using preparative chromatography approaches and characterization using analytical chromatography and mass spectrometry. Engagement fit is strongest when project goals prioritize conjugation yield, residual unconjugated antibody reduction, and stability-focused assay packages.

A practical tradeoff appears in dependency on project inputs for best outcomes, since route decisions for linker design and coupling strategy depend on chemistry intent and downstream assay constraints. Sino Biological is a strong usage situation for programs moving from method development into scaled manufacturing steps where batch comparability matters more than exploratory turnaround.

GenScript supports managed conjugation workflows that typically begin with linker and coupling strategy selection for formats like antibody–drug conjugates and antibody–oligonucleotide conjugates. The delivery model emphasizes controlled conjugation conditions and downstream purification steps, then pairs them with analytics that quantify conjugate quality using chromatography and size-based methods. This approach tends to work well for research teams that need consistent batch-to-batch behavior when moving from screening material into later characterization stages.

A tradeoff is that tight process discipline can slow projects that want rapid iteration of multiple conjugation variants per week, because each change usually triggers a structured re-run of method and analytical framing. GenScript is a strong fit when the work includes linker-specific constraints, such as cleavable versus non-cleavable linkage requirements, or when release-oriented analytics like residual unconjugated antibody quantitation matter for decision-making. For teams with one lead construct and a clear analytical target, this model reduces rework risk and supports cleaner comparisons across timepoints.

GenScript’s engagement is also well-suited for projects that expect scale-up and tech transfer considerations, since the documentation and characterization flow are built around reproducibility rather than ad hoc handoffs. Teams planning method validation or stability-indicating studies benefit from analytics that can be carried forward into later bioanalytical planning without rewriting the entire characterization narrative.

Catalent supports bioconjugation work that spans antibody–drug conjugates, antibody–oligonucleotide conjugates, and protein labeling, with a delivery model built around chemistry development and manufacture. The practical differentiator is the end-to-end coupling-to-fill workflow that keeps linker selection, conjugation process control, and purification planning tied to the intended analytical package.

Thermo Fisher Scientific delivers bioconjugation work that supports antibody–drug conjugates, antibody–oligonucleotide conjugates, and protein labeling through controlled conjugation and downstream purification. The service focus centers on linker design choices, release specification support, and analytical workflows that quantify free payload and residual unconjugated species.

BOC Sciences supports bioconjugation work across common research formats for protein labeling, peptide–drug conjugates, and antibody–drug conjugates, with a workflow centered on executed chemistry rather than software tooling. It offers both random and site-specific conjugation options, including lysine-focused and engineered-cysteine styles, plus linker and payload handling that targets measurable conjugation yield and removal of residual starting material.

Samsung Biologics is distinct as a vertically integrated CDMO with bioconjugation services tied to broader biologics development and manufacturing experience. Core offerings center on antibody and protein labeling workflows that support antibody–drug conjugates and antibody–oligonucleotide conjugates, plus downstream purification such as preparative chromatography to reach defined release profiles.

CellMosaic provides bioconjugation services that focus on producing conjugates for antibody and protein labeling workflows, including ADC-style constructs and nucleic-acid conjugates. Delivery is anchored in practical lab execution that includes formulation work, purification, and analytical characterization designed to quantify key release attributes like conjugation yield and residual unconjugated material.

Creative Biolabs performs small-scale to research-scale bioconjugation for applications that include antibody–drug conjugates, peptide–drug conjugates, and protein labeling. The service emphasizes practical chemistry execution across multiple coupling modes, including thiol-based linkages and azide–alkyne click style routes, plus purification and analytical characterization workflows used to assess conjugation outcomes.

Abzena is a bioconjugation service provider that focuses on manufacturing-grade conjugates for research groups, including antibody–drug conjugates and antibody–oligonucleotide conjugates. Core capabilities include protein labeling, linker-centric workflows, and purification plus analytics suited for assessing conjugation yield and residual unconjugated species. The delivery model emphasizes development through scale-up and tech transfer, which supports continuity when projects move from characterization to production batches.